Manufacturing, Cell-Line Selection

Thermo Fisher’s new centrifuge technology is designed to enable efficient, sustainable cell culture harvesting.

Catalent Biologics has launched its new cell line expression technology, GPEx Lightning, which aims to shorten drug substance development timelines by up to three months.

The emergence of new biotherapeutics is both the driver and result of innovative drug development technologies.

The company has introduced Opto Assure, a series of assays that provide yield and product quality data at an earlier stage in cell-line development.

Samsung Biologics has adopted Solentim’s cell seeding and cell metric platforms at its new R&D center in San Francisco, CA.

Mogrify’s new technology platform, EpiMOGRIFY, can predict cellular switches important for determining cell identity, cell maintenance, directed differentiation, and cell conversion.

The company has made several moves in recent weeks to expand manufacturing capacity and cell line services.

The candidates will be used by the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

Catalent will use its GPEx cell line development technology to create a cell line expressing the recombinant VLP at its Madison, WI facility.

Solentim and ATUM will bundle together the Leap-In Transposase platform with the VIPS single cell cloning instrument for cell line development.

This milestone achievement will allow the companies to move forward with developing a GMP-compliant manufacturing process for clinical testing.

Abcam has purchased Applied StemCell’s (ASC’s) gene editing platform and oncology product portfolio, adding comprehensive cell editing capabilities and engine to support expansion of existing “off-the-shelf” cell lines.

The next-generation gene editing system can be applied to the development of novel cell and gene therapies.

ProBioGen and Lava Therapeutics have closed the cell line development and manufacturing agreement for Lava’s novel bispecific antibody lead candidate.

Through the collaboration, Charles River plans to expand its suite of authentic human cells by utilizing Bit Bio’s target discovery, validation, and screening services to further the development of therapies with a higher chance of success in patients.

The technology is set to heighten the company’s GPEx expression platform through the utilization of a glutamine synthase knock-out Chinese hamster ovary cell line.

Manufacturing of the cell line will take place at Lonza’s GMP facility in Geleen, Netherlands.

The company has launched new services for mammalian cell bank manufacturing under GMP conditions.

The $10-million investment will include a 500-L single-use perfusion bioreactor and seven patented downstream processing units.

Agenus will leverage Selexis’ SUREtechnology Platform to progress Agenus’ portfolio of next-generation antibody programs.

This article will explore the requirements for media and supplements needed to maintain newer cell lines, such as those based on human cells and fungal cells.

The company will collaborate with GlycoBac to offer an insect cell line for the development of viral vaccines and gene therapies.

Cell-line quality has a significant impact on biologic drug quality; learn more about this and other upstream challenges at the new bioLIVE launching this year adjacent to CPhI Worldwide 2018.

Development costs and time to market continue to put pressure on the biopharma industry, driving the need for innovation in methods and technologies.

Catalent Biologics will adopt Berkeley Lights’ Beacon optofluidic platform for its cell-line development workflow.

Biopharma seeks alternatives that meet the needs for next-gen biologic drug production.

The new platform is expected to speed up cell line development.

Under this agreement, the companies will develop in parallel an antibody drug candidate and cell lines for other potential candidates.

The study suggests that circumventing evolution in cell factories can enable the commercialization of new biobased chemicals to large-scale.

Gilead Sciences will acquire Cell Design Labs to further cell-therapy research and development efforts.